Nuevas dianas y riesgo de ETV
Vía c-met
VÍAc-MET EN CÁNCER GASTRO-ESOFÁGIC
Ornatuzumab ASCO 2015 A4012
•
MetMAb monovalent humanized antibody blocks HGF binding and
receptor activation (MET/HGF pathway)
•
FOLFOX+ornatuzumab phase III METGastric study
•
PE: ornatuzumab 6.1% vs placebo 3.6%
Rilotumumab
•
Fully human monoclonal antibody to hepatocyte growth factor/scatter
factor that inhibits signaling through the MET receptor
•
Phase 3 RILOMET-1 study. ECX+Rilotumumab
•
DVT: rilotumumab 9.1% vs placebo 3.3%
•
Phase 2 PRODIGE 17-ACCORD 20 MEGA: FOLFOX+rilotumab
•
VTE: FOLFOX-rilotummab 18% (grade 5) vs FOLFOX 9% vs FOLFOX-
panitumumab 4%
